Guy Berchem
Latest publications
Autophagic degradation of GZMB/granzyme B: a new mechanism of hypoxic tumor cell escape from natural killer cell-mediated lysis.
- Tumor Immunotherapy and Microenvironment
- Tumor Stroma Interactions
2014 Jan. Autophagy.10(1):173-5. Epub 2013 Nov 15.
The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity.
- Tumor Immunotherapy and Microenvironment
- Tumor Stroma Interactions
2013 Dec. Front Immunol.4:490.
Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia.
- Tumor Immunotherapy and Microenvironment
- NORLUX Neuro-Oncology Laboratory
2013 Oct. Proc Natl Acad Sci U S A.110(43):17450-5. Epub 2013 Oct 7.
Stromal cell-induced miRNA alteration in chronic lymphocytic leukemia: how a minute and unavoidable cell contamination impairs miRNA profiling.
- Tumor Stroma Interactions
2013 Aug. Leukemia.27(8):1773-6. Epub 2013 Feb 14.
Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F.
- Tumor Immunotherapy and Microenvironment
2013 Feb. J Cell Mol Med.17(2):265-76. Epub 2013 Jan 10.
Hypoxia-induced autophagy: a new player in cancer immunotherapy?
- Tumor Immunotherapy and Microenvironment
2012 Apr. Autophagy.8(4):704-6. Epub 2012 Apr 1.
Lung cancer statistics in Luxembourg from 1981 to 2008.
- Tumor Immunotherapy and Microenvironment
- Proteomics of Cellular Signaling
2011 Dec. Bull Soc Sci Med Grand Duche Luxemb.(2):43-55.
The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain.
- Tumor Immunotherapy and Microenvironment
2011 Oct. BMC Med Genet.12:144.
Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression.
- Tumor Immunotherapy and Microenvironment
- Tumor Stroma Interactions
2011 Sep. Cancer Res.71(18):5976-86. Epub 2011 Aug 2.
The acquisition of resistance to TNFalpha in breast cancer cells is associated with constitutive activation of autophagy as revealed by a transcriptome analysis using a custom microarray.
- Tumor Stroma Interactions
- Tumor Immunotherapy and Microenvironment
- Platform LUXGEN - Micro-Array
2011 Jul. Autophagy.7(7):760-70. Epub 2011 Jul 1.
MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia.
- Tumor Stroma Interactions
- Tumor Immunotherapy and Microenvironment
- Platform LUXGEN - Micro-Array
2011 Apr. Proc Natl Acad Sci U S A.108(16):6573-8. Epub 2011 Apr 1.
A population based economic analysis of cross-border payments for fertility services in Luxembourg.
- Public Health Research
2010 Oct. J Exp Clin Assist Reprod.7:pii: 3.
The actin filament cross-linker L-plastin confers resistance to TNF-alpha in MCF-7 breast cancer cells in a phosphorylation-dependent manner.
- Tumor Immunotherapy and Microenvironment
- Platform LUXGEN - Micro-Array
2010 Jun. J Cell Mol Med.14(6A):1264-75. Epub 2009 Oct 3.
Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
- Tumor Stroma Interactions
- Tumor Immunotherapy and Microenvironment
- Platform LUXGEN - Micro-Array
2010 May. Mol Cancer.9(1):115. emoussay, vpalissot, lvallar, $, $, velkhoury, naouali, kvanmoer, bleners, fbernardin, .amuller, $, $, $, $, evandyck, gberchem.
The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade.
- Tumor Stroma Interactions
- Tumor Immunotherapy and Microenvironment
- Platform National Cytometry
2010 Apr. Mol Cancer Ther.9(5):1349-60. Epub 2010 Apr 20.
Challenges with advanced therapy medicinal products and how to meet them.
- Tumor Immunotherapy and Microenvironment
2010 Mar. Nat Rev Drug Discov.9(3):195-201.
Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?
- Tumor Immunotherapy and Microenvironment
2010 Jan. Tissue Antigens.75(1):1-8.